Tuesday, April 16, 2024

FDA Alerts on Complications Risks of Hologic’s Biozorb Following Reports of Displacement and Injury

Similar articles

The Food and Drug Administration (FDA) has issued a safety communication alerting healthcare providers to the potential risk of serious complications associated with Hologic’s Biozorb Markers. This warning comes in response to reports indicating that these radiographic markers may move out of position, penetrate the skin, and lead to other adverse events. In light of these complications concerns, the FDA is reminding physicians about the authorized indications for these markers and advising them to closely monitor patients who have received them.

Hologic, the manufacturer of Biozorb products, has published a safety notification regarding potential complications associated with these implants. Currently, the company is facing lawsuits from 84 plaintiffs who allege injuries related to the use of Biozorb implants.

Focal Therapeutics, a company renowned for its innovative medical technologies, initially developed the Biozorb tissue marker as a groundbreaking solution for marking sites in soft tissue requiring radiation therapy as part of cancer treatment protocols. This innovative device aimed to enhance the precision and efficacy of cancer treatment by providing healthcare professionals with a reliable tool for accurately identifying target areas within the body.

Recognizing the immense potential of Biozorb and its impact on cancer care, Hologic, a global leader in women’s health and medical imaging technologies, made a strategic move to acquire Focal Therapeutics in 2018 for a substantial sum of $125 million. This acquisition marked a significant milestone in Hologic’s commitment to advancing cancer care and bolstering its portfolio of cutting-edge medical devices.

Revolutionizing Cancer Care: The Innovative Biozorb Tissue Marker by Focal Therapeutics

The original Biozorb tissue marker received 510(k) clearance from the Food and Drug Administration (FDA) in 2012, signifying its compliance with regulatory standards and its approval for clinical use in the United States. Building upon this success, Focal Therapeutics continued its dedication to innovation by developing the Biozorb LP Marker, a low-profile version of the device, which obtained FDA clearance in 2015.

Both iterations of the Biozorb marker share a common objective: to facilitate the precise localization of target tissues requiring radiation therapy while minimizing the impact on surrounding healthy tissues. A key feature of these markers is their incorporation of a resorbable plastic component, designed to gradually dissolve within the body over one year or longer. This unique characteristic ensures that the markers fulfill their intended purpose during treatment and subsequently dissipate without the need for removal procedures.

The introduction of the Biozorb markers represented a significant advancement in the field of oncology, offering healthcare professionals a valuable tool for improving treatment outcomes and enhancing patient care. By providing clinicians with a reliable means of identifying and tracking target sites for radiation therapy, Biozorb has contributed to more precise treatment delivery and optimized therapeutic outcomes for cancer patients.

Through its acquisition of Focal Therapeutics and the Biozorb technology, Hologic reaffirmed its commitment to innovation and excellence in cancer care. The company’s continued investment in advancing medical technologies underscores its dedication to addressing unmet clinical needs and improving patient outcomes in the fight against cancer.


Complications and Litigation Surrounding Hologic’s Biozorb Implants Raise Concerns

Reports of complications associated with Biozorb implants have surfaced, prompting concerns among healthcare professionals. Physicians have documented cases where the implants eroded through the skin, resulting in recurrent infections and pain for affected patients. Additionally, the FDA has received adverse event reports indicating complications such as infection, fluid buildup, and pain, possibly linked to extended resorption time of the implant components.

In response to these reports, the FDA has emphasized that Biozorb markers are intended solely for radiographic marking purposes and not for tissue filling or cosmetic enhancement. Healthcare providers are urged to discuss the benefits and complications of these implants with patients and to monitor them closely for any signs of complications.

The lawsuits filed against Hologic allege that patients experienced undisclosed side effects not mentioned in the Biozorb instructions for use. While Hologic maintains that it has valid defenses against these claims and intends to vigorously defend its position, the company acknowledges the uncertainty and potential costs associated with litigation. At this stage, the outcome of these legal proceedings remains uncertain, with a tentative trial date set for November 2025 for one of the complaints, and others pending in the U.S. District Court for the District of Massachusetts.


Resource: Med Tech Dive, February 28, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article